{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:48:39Z","timestamp":1787539719264,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009827","name":"Laura and John Arnold Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We explored whether clinically relevant baseline characteristics of patients with type 2 diabetes can modify the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on the risk of major adverse cardiovascular events (MACE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated Medline and EMBASE through June 2019. We included randomized clinical trials reporting the effect of GLP-1 RA or SGLT-2i on MACE in subgroups of patients with type 2 diabetes, identified through key baseline factors: established cardiovascular disease; heart failure; chronic kidney disease; uncontrolled diabetes; duration of diabetes; hypertension; obesity; age; gender and race. Hazard ratios (HRs) and 95% confidence intervals (CIs) from trials were meta-analyzed using random-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten trials enrolling 89,790 patients were included in the analyses. Subgroup meta-analyses showed a 14% risk reduction of MACE in patients with established cardiovascular disease [GLP1-RA: HR, 0.86 (95% CI, 0.80\u20130.93); SGLT-2i: 0.86 (0.80\u20130.93)], and no effect in at-risk patients without history of cardiovascular events [GLP1-RA: 0.94 (0.82\u20131.07); SGLT-2i: 1.00 (0.87\u20131.16)]. We observed a trend toward larger treatment benefits with SGLT-2i among patients with chronic kidney disease [0.82 (0.69\u20130.97)], and patients with uncontrolled diabetes for both GLP1-RA or SGLT-2i [GLP1-RA: 0.82 (0.71\u20130.95); SGLT-2i: 0.84 (0.75\u20130.95)]. Uncontrolled hypertension, obesity, gender, age and race did not appear to modify the effect of these drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this exploratory analysis, history of cardiovascular disease appeared to modify the treatment effect of SGLT2i or GLP1-RA on MACE. Chronic kidney disease and uncontrolled diabetes should be further investigated as potential effect modifiers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-020-01133-1","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T09:02:49Z","timestamp":1601370169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-3964","authenticated-orcid":false,"given":"Elvira","family":"D\u2019Andrea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily H.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer Phillips","family":"Hey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"1133_CR1","unstructured":"Murphy SL, Xu J, Kochanek KD, Arias E. Centers for Disease Control and Prevention. National Center for Health Statistics. Mortality in the United States, 2017. NCHS Data Brief No. 328, November 2018. https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db328-h.pdf (accessed Jan 10th, 2020)."},{"issue":"3","key":"1133_CR2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11121-014-0513-z","volume":"16","author":"EA Stuart","year":"2015","unstructured":"Stuart EA, Bradshaw CP, Leaf PJ. Assessing the generalizability of randomized trial results to target populations. Prev Sci. 2015;16(3):475\u201385.","journal-title":"Prev Sci"},{"issue":"5","key":"1133_CR3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/EDE.0b013e318127181b","volume":"18","author":"TJ VanderWeele","year":"2007","unstructured":"VanderWeele TJ, Robins JM. Four types of effect modification: a classification based on directed acyclic graphs. Epidemiology. 2007;18(5):561\u20138.","journal-title":"Epidemiology."},{"issue":"1","key":"1133_CR4","first-page":"55","volume":"1","author":"TJ Vander Weele","year":"2012","unstructured":"Vander Weele TJ. Confounding and effect modification: distribution and measure. Epidemiol Methods. 2012;1(1):55\u201382.","journal-title":"Epidemiol Methods."},{"key":"1133_CR5","doi-asserted-by":"crossref","unstructured":"Chin R, Lee BY. Section V: Analysis of Results. In: Principles and Practice of Clinical Trial Medicine, 2008. Academic Press: Cambridge.","DOI":"10.1016\/B978-0-12-373695-6.00015-6"},{"key":"1133_CR6","doi-asserted-by":"crossref","unstructured":"Guralnik JM, Manolio TA. Chapter 16: Design and Conduct of Observational Studies and Clinical Trials. In: Gallin JI, Ognibene FP, eds. Principles and Practice of Clinical Research, 2nd Edition, 2007. Academic Press: Cambridge.","DOI":"10.1016\/B978-012369440-9\/50020-7"},{"issue":"17","key":"1133_CR7","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019;139(17):2022\u201331.","journal-title":"Circulation"},{"issue":"10166","key":"1133_CR8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"key":"1133_CR9","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"key":"1133_CR10","unstructured":"US Department of Health and Human Services Food and Drug Administration. Guidance for Industry. Diabetes Mellitus \u2010 Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm071627.pdf (accessed Jan 10th, 2020)."},{"key":"1133_CR11","doi-asserted-by":"publisher","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. Epub: June 09, 2019. https:\/\/doi.org\/10.1016\/s0140-6736(19)31149-3.","DOI":"10.1016\/s0140-6736(19)31149-3"},{"issue":"7303","key":"1133_CR12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","volume":"323","author":"P Juni","year":"2001","unstructured":"Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001;323(7303):42\u20136.","journal-title":"BMJ"},{"issue":"3","key":"1133_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"2","key":"1133_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97\u2013111.","journal-title":"Res Synth Methods."},{"key":"1133_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/sim.4780140406","volume":"14","author":"CS Berkey","year":"1995","unstructured":"Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Stat Med. 1995;14:395\u2013411.","journal-title":"Stat Med"},{"issue":"4","key":"1133_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/1536867X0800800403","volume":"8","author":"RM Harbord","year":"2008","unstructured":"Harbord RM, Higgins JPT. Meta-regression in Stata. Stata Journal. 2008;8(4):493\u2013519.","journal-title":"Stata Journal"},{"issue":"7414","key":"1133_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"8","key":"1133_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1503\/cmaj.060410","volume":"176","author":"JP Ioannidis","year":"2007","unstructured":"Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ Can Med Assoc J. 2007;176(8):1091\u20136.","journal-title":"CMAJ Can Med Assoc J."},{"key":"1133_CR19","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"issue":"7","key":"1133_CR20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s11606-013-2755-z","volume":"29","author":"KJ Rothman","year":"2014","unstructured":"Rothman KJ. Six persistent research misconceptions. J Gen Intern Med. 2014;29(7):1060\u20134.","journal-title":"J Gen Intern Med"},{"key":"1133_CR21","doi-asserted-by":"crossref","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247\u20132257.","DOI":"10.1056\/NEJMoa1509225"},{"key":"1133_CR22","doi-asserted-by":"crossref","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311\u2013322.","DOI":"10.1056\/NEJMoa1603827"},{"key":"1133_CR23","doi-asserted-by":"crossref","unstructured":"Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834\u20131844.","DOI":"10.1056\/NEJMoa1607141"},{"key":"1133_CR24","doi-asserted-by":"crossref","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al.; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228\u20131239.","DOI":"10.1056\/NEJMoa1612917"},{"key":"1133_CR25","doi-asserted-by":"crossref","unstructured":"Hernandez AF, Green JB, Janmohamed S, et al.; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018,392(10157):1519-1529.","DOI":"10.1016\/S0140-6736(18)32261-X"},{"key":"1133_CR26","doi-asserted-by":"crossref","unstructured":"Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"1133_CR27","doi-asserted-by":"crossref","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644\u2013657.","DOI":"10.1056\/NEJMoa1611925"},{"key":"1133_CR28","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.; DECLARE\u2013TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019. 380(4):347-357."},{"key":"1133_CR29","doi-asserted-by":"crossref","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al.; for the PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-851.","DOI":"10.1056\/NEJMoa1901118"},{"key":"1133_CR30","doi-asserted-by":"crossref","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears in Diabetes Care. 2020 Jul;43(7):1670]. Diabetes Care. 2020;43(2):487-493.","DOI":"10.2337\/dci19-0066"},{"issue":"8","key":"1133_CR31","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/dom.13740","volume":"21","author":"C Hupfeld","year":"2019","unstructured":"Hupfeld C, Mudaliar S. Navigating the \u201cMACE\u201d in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits. Diabetes Obes Metab. 2019;21(8):1780\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1133_CR32","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4239\/wjd.v10.i6.324","volume":"10","author":"R Kant","year":"2019","unstructured":"Kant R, Munir KM, Kaur A, Verma V. Prevention of macrovascular complications in patients with type 2 diabetes mellitus: review of cardiovascular safety and efficacy of newer diabetes medications. World J Diabetes. 2019;10(6):324\u201332.","journal-title":"World J Diabetes."},{"issue":"4","key":"1133_CR33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.pcad.2019.08.003","volume":"62","author":"T Acharya","year":"2019","unstructured":"Acharya T, Deedwania P. Cardiovascular outcome trials of the newer anti-diabetic medications. Prog Cardiovasc Dis. 2019;62(4):342\u20138.","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"1133_CR34","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/dom.13649","volume":"21","author":"KS Boye","year":"2019","unstructured":"Boye KS, Riddle MC, Gerstein HC, et al. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. Diabetes Obes Metab. 2019;21(6):1299\u2013304.","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"1133_CR35","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"1","key":"1133_CR36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-019-0938-6","volume":"18","author":"M Packer","year":"2019","unstructured":"Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovasc Diabetol. 2019;18(1):129.","journal-title":"Cardiovasc Diabetol."},{"key":"1133_CR37","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"1","key":"1133_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","volume":"17","author":"AC Sposito","year":"2018","unstructured":"Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK, et al. Cardiovasc Diabetol. 2018;17(1):157.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"1133_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-019-0942-x","volume":"18","author":"LE Clegg","year":"2019","unstructured":"Clegg LE, Penland RC, Bachina S, et al. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol. 2019;18(1):138.","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"1133_CR40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(20)30038-3","volume":"8","author":"OR Ghosh-Swaby","year":"2020","unstructured":"Ghosh-Swaby OR, Goodman SG, Leiter LA, Cheng A, Connelly KA, Fitchett D, J\u00fcni P, Farkouh ME, Udell JA, Ghosh-Swaby OR, et al. Lancet Diabetes Endocrinol. 2020;8(5):418\u201335.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"1133_CR41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","volume":"18","author":"Y Fei","year":"2019","unstructured":"Fei Y, Tsoi MF, Cheung BMY. Cardiovasc Diabetol. 2019;18(1):112.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"1133_CR42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-019-0853-x","volume":"18","author":"DY Yang","year":"2019","unstructured":"Yang DY, He X, Liang HW, Zhang SZ, Zhong XB, Luo CF, Du ZM, He JG, Zhuang XD, Liao XX, Yang DY, et al. Cardiovasc Diabetol. 2019;18(1):47.","journal-title":"Cardiovasc Diabetol."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01133-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T20:32:28Z","timestamp":1632861148000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01133-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1133"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01133-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-30056\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-30056\/v2","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}